New C2H Reports: Daratumumab Vorhyaluronidase Alfa (Darzquro) and Polatuzumab Vedotin (Polivy)

Reports of the cost-effectiveness evaluation on Daratumumab Vorhyaluronidase Alfa (Darzquro) and Polatuzumab Vedotin (Polivy) were released.